Diamyd Medical

Diamyd Medical

Tillverkning av läkemedel

Developing precision medicine therapies for Type 1 Diabetes

Om oss

Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for Type 1 Diabetes. The therapeutic diabetes vaccine Diamyd , an antigen-specific immunotherapy for the preservation of endogenous insulin production, is being evaluated in the ongoing Phase III trial DIAGNODE-3. The company is establishing a vaccine manufacturing facility in Umeå for the manufacture of recombinant GAD65, the active ingredient in the diabetes vaccine. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB. The Diamyd Medical share is traded on Nasdaq First North Growth Market, ticker DMYD B.

Bransch
Tillverkning av läkemedel
Företagsstorlek
11–50 anställda
Huvudkontor
Stockholm
Typ
Publikt aktiebolag
Specialistområden
Autoimune Diabetes (Type 1 Diabetes and LADA), Pre-clinical and Clinical Development, Development of Combination Therapies for the Treatment of Autoimmune Diabetes, Preserving Beta Cell Function, Pharmaceutical Development och Targeted Immunotherapy

Adresser

Anställda på Diamyd Medical

Uppdateringar

Liknande sidor

Finansiering

Diamyd Medical 5 rundor totalt

Senaste finansieringsrunda

Aktiekapital efter börsintroduktion

4 672 724,00 US$

Se mer info på crunchbase